PT3363438T - 2-azabiciclos substituídos e sua utilização como moduladores de recetores de orexina - Google Patents
2-azabiciclos substituídos e sua utilização como moduladores de recetores de orexinaInfo
- Publication number
- PT3363438T PT3363438T PT172064917T PT17206491T PT3363438T PT 3363438 T PT3363438 T PT 3363438T PT 172064917 T PT172064917 T PT 172064917T PT 17206491 T PT17206491 T PT 17206491T PT 3363438 T PT3363438 T PT 3363438T
- Authority
- PT
- Portugal
- Prior art keywords
- azabicycles
- substituted
- receptor modulators
- orexin receptor
- orexin
- Prior art date
Links
- 108050000742 Orexin Receptor Proteins 0.000 title 1
- 102000008834 Orexin receptor Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780378P | 2013-03-13 | 2013-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3363438T true PT3363438T (pt) | 2019-12-11 |
Family
ID=50487148
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT172064917T PT3363438T (pt) | 2013-03-13 | 2014-03-12 | 2-azabiciclos substituídos e sua utilização como moduladores de recetores de orexina |
| PT147175764T PT2970314T (pt) | 2013-03-13 | 2014-03-12 | 2-azabiciclos substituídos e sua utilização como moduladores dos recetores de orexina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT147175764T PT2970314T (pt) | 2013-03-13 | 2014-03-12 | 2-azabiciclos substituídos e sua utilização como moduladores dos recetores de orexina |
Country Status (38)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03452B (me) | 2009-10-23 | 2020-01-20 | Janssen Pharmaceutica Nv | Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora |
| EP2937345B1 (en) | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| JP6106685B2 (ja) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤 |
| TWI621618B (zh) * | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途 |
| TW201444821A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代之哌啶化合物及其作為食慾素受體調節劑之用途 |
| TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
| WO2015131773A1 (zh) * | 2014-03-06 | 2015-09-11 | 上海海雁医药科技有限公司 | 作为食欲素受体拮抗剂的哌啶衍生物 |
| JP6715239B2 (ja) * | 2014-09-11 | 2020-07-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換２−アザ二環式化合物及びオレキシン受容体調節因子としてのその使用 |
| US9938276B2 (en) * | 2014-12-19 | 2018-04-10 | Merck Sharp & Dohme Corp. | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists |
| US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| US10196383B2 (en) | 2015-07-17 | 2019-02-05 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
| CN111499625B (zh) * | 2015-08-14 | 2022-09-02 | 上海海雁医药科技有限公司 | 食欲素受体拮抗剂受体化合物的制备方法及其中间体和晶型 |
| WO2017044858A2 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| US10370380B2 (en) | 2015-11-23 | 2019-08-06 | Sunshine Lake Pharma Co., Ltd. | Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof |
| KR20230116948A (ko) | 2016-03-10 | 2023-08-04 | 얀센 파마슈티카 엔.브이. | 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법 |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| JP7258748B2 (ja) | 2016-11-22 | 2023-04-17 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用 |
| ES2982801T3 (es) | 2017-03-28 | 2024-10-17 | Gilead Sciences Inc | Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas |
| GB2558975B (en) * | 2017-09-01 | 2019-01-23 | Chronos Therapeutics Ltd | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists |
| CA3074059A1 (en) | 2017-09-01 | 2019-03-07 | Chronos Therapeutics Limited | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists |
| EP3810132A4 (en) | 2018-06-25 | 2022-06-22 | Dana-Farber Cancer Institute, Inc. | TAIRE FAMILY KINASE INHIBITORS AND RELATED USES |
| CN113164477A (zh) * | 2018-12-14 | 2021-07-23 | 达纳-法伯癌症研究所股份有限公司 | C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途 |
| EP3902542A4 (en) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | CYCLIN DEPENDENT KINASE 7 INHIBITORS AND USES THEREOF |
| KR102692309B1 (ko) | 2019-01-15 | 2024-08-07 | 길리애드 사이언시즈, 인코포레이티드 | Fxr (nr1h4) 조정 화합물 |
| WO2020172075A1 (en) | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| GB202416792D0 (en) | 2024-11-14 | 2025-01-01 | Bial Portela & Ca Sa | Orexin receptor antagonists: 2-azabicyclic compounds |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3674793A (en) | 1967-03-29 | 1972-07-04 | Sterling Drug Inc | 6-hydroxy-2-azabicyclo(2.2.2)octan-3-ones and 2-azabicyclo(2.2.2.)octane-3,6-diones |
| US6505492B2 (en) | 2001-04-11 | 2003-01-14 | Bethlehem Steel Corporation | Method and apparatus for forming deep-drawn articles |
| US20040176361A1 (en) | 2001-05-23 | 2004-09-09 | Masakazu Fujio | Fused heterocyclic compound and medicinal use thereof |
| EP1594852A1 (en) | 2003-02-07 | 2005-11-16 | Ranbaxy Laboratories, Ltd. | Oxazolidinone derivatives as antimicrobials |
| CA2516329A1 (en) | 2003-02-21 | 2004-09-02 | Pharmacia & Upjohn Company Llc | Exo-(t-butyl 2r(+))-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate, intermediates, and process to prepare and isolate them |
| BRPI0620066A2 (pt) | 2005-12-20 | 2011-11-01 | Novartis Ag | derivados de ácido nicotìnico como moduladores do receptor de glutamato metabotrópico, processo para preparação dos mesmos, composição farmacêutica e uso dos referidos derivados |
| EP2272509A1 (en) | 2006-09-11 | 2011-01-12 | Novartis AG | New Uses of metabotropic glutamate receptors |
| CN101568533A (zh) | 2006-12-01 | 2009-10-28 | 埃科特莱茵药品有限公司 | 3-异芳基(氨基或酰胺基)-1-(联苯或苯基噻唑基)羰基哌啶衍生物食欲素受体抑制剂 |
| AR064561A1 (es) | 2006-12-28 | 2009-04-08 | Actelion Pharmaceuticals Ltd | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. |
| US8030495B2 (en) * | 2007-05-23 | 2011-10-04 | Coleman Paul J | Cyclopropyl pyrrolidine orexin receptor antagonists |
| PL2170864T3 (pl) | 2007-07-17 | 2012-02-29 | Bristol Myers Squibb Co | Agoniści receptora gpr119 sprężonego z białkiem g - pirydon |
| KR101204213B1 (ko) | 2007-12-21 | 2012-11-26 | 에프. 호프만-라 로슈 아게 | 오렉신 수용체 길항제로서의 헤테로아릴 유도체 |
| AU2009215243A1 (en) * | 2008-02-21 | 2009-08-27 | Actelion Pharmaceuticals Ltd. | 2-aza-bicyclo[2.2.1]heptane derivatives |
| JP2011519849A (ja) | 2008-04-30 | 2011-07-14 | アクテリオン ファーマシューティカルズ リミテッド | ピペリジン及びピロリジン化合物 |
| MX2011000664A (es) | 2008-07-16 | 2011-02-24 | Schering Corp | Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119. |
| AU2009307915A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
| AU2009307920A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,3-disubstituted piperidine orexin receptor antagonists |
| CA2745433A1 (en) | 2008-12-02 | 2010-06-10 | Glaxo Group Ltd. | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof |
| AR076024A1 (es) | 2009-04-03 | 2011-05-11 | Schering Corp | Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos |
| CN102459229A (zh) | 2009-04-24 | 2012-05-16 | 葛兰素集团有限公司 | 用作食欲肽拮抗剂的3-氮杂二环[4.1.0]庚烷 |
| EP2491031B1 (en) | 2009-10-23 | 2013-08-07 | Janssen Pharmaceutica N.V. | Fused heterocyclic compounds as orexin receptor modulators |
| EP2491034B1 (en) | 2009-10-23 | 2013-12-18 | Janssen Pharmaceutica, N.V. | Fused heterocyclic compounds as orexin receptor modulators |
| ME03452B (me) | 2009-10-23 | 2020-01-20 | Janssen Pharmaceutica Nv | Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora |
| CA2778684A1 (en) | 2009-10-29 | 2011-05-05 | Schering Corporation | Bridged bicyclic piperidine derivatives and methods of use thereof |
| US9301929B2 (en) | 2009-11-24 | 2016-04-05 | Merck Sharp & Dohme Corp. | Substituted biaryl derivatives and methods of use thereof |
| WO2011075415A1 (en) | 2009-12-14 | 2011-06-23 | Inspire Pharmaceuticals, Inc. | Bridged bicyclic rho kinase inhibitor compounds, composition and use |
| US8697691B2 (en) | 2009-12-21 | 2014-04-15 | Vanderbilt University | Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective M1 agonists and methods of making and using same |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| US20130096141A1 (en) | 2010-06-18 | 2013-04-18 | Bernard R. Neustadt | Bicyclic heterocycle derivatives and methods of use thereof |
| WO2012089606A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists |
| WO2012145581A1 (en) | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| WO2014066196A1 (en) | 2012-10-23 | 2014-05-01 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-3-substituted-4-nitrile orexin receptor antagonists |
| MX2015006191A (es) | 2012-11-16 | 2015-08-10 | Merck Sharp & Dohme | Inhibidores de purina de fosfatidilinositol 3-quinasa delta humana. |
| TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
| TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途 |
| MX2016010056A (es) | 2014-02-06 | 2016-11-15 | Abbvie Inc | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. |
| JP6715239B2 (ja) | 2014-09-11 | 2020-07-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換２−アザ二環式化合物及びオレキシン受容体調節因子としてのその使用 |
-
2014
- 2014-03-11 TW TW103108293A patent/TWI621618B/zh not_active IP Right Cessation
- 2014-03-12 CN CN201810842686.7A patent/CN108864093A/zh active Pending
- 2014-03-12 EP EP14717576.4A patent/EP2970314B1/en active Active
- 2014-03-12 WO PCT/US2014/024293 patent/WO2014165070A1/en not_active Ceased
- 2014-03-12 CA CA2904618A patent/CA2904618C/en active Active
- 2014-03-12 SM SM20230223T patent/SMT202300223T1/it unknown
- 2014-03-12 ES ES17206491T patent/ES2760564T3/es active Active
- 2014-03-12 US US14/774,555 patent/US9611277B2/en active Active
- 2014-03-12 PT PT172064917T patent/PT3363438T/pt unknown
- 2014-03-12 PL PL19193122.9T patent/PL3622956T3/pl unknown
- 2014-03-12 RS RSP20191419 patent/RS59466B1/sr unknown
- 2014-03-12 SM SM20190655T patent/SMT201900655T1/it unknown
- 2014-03-12 HU HUE14717576A patent/HUE036193T2/hu unknown
- 2014-03-12 ME MEP-2019-314A patent/ME03572B/me unknown
- 2014-03-12 PL PL17206491T patent/PL3363438T3/pl unknown
- 2014-03-12 PE PE2015001954A patent/PE20151599A1/es active IP Right Grant
- 2014-03-12 LT LT17206491T patent/LT3363438T/lt unknown
- 2014-03-12 LT LTEP14717576.4T patent/LT2970314T/lt unknown
- 2014-03-12 PL PL14717576T patent/PL2970314T3/pl unknown
- 2014-03-12 UA UAA201509932A patent/UA118669C2/uk unknown
- 2014-03-12 CN CN201910948604.1A patent/CN110669052B/zh active Active
- 2014-03-12 ES ES19193122T patent/ES2950032T3/es active Active
- 2014-03-12 SM SM20180056T patent/SMT201800056T1/it unknown
- 2014-03-12 KR KR1020157028720A patent/KR102209424B1/ko not_active Expired - Fee Related
- 2014-03-12 MX MX2015011815A patent/MX361529B/es active IP Right Grant
- 2014-03-12 BR BR112015022294-3A patent/BR112015022294B1/pt active IP Right Grant
- 2014-03-12 SI SI201430542T patent/SI2970314T1/en unknown
- 2014-03-12 SG SG11201507415QA patent/SG11201507415QA/en unknown
- 2014-03-12 ES ES14717576.4T patent/ES2659397T3/es active Active
- 2014-03-12 MY MYPI2015703021A patent/MY183725A/en unknown
- 2014-03-12 SI SI201431351T patent/SI3363438T1/sl unknown
- 2014-03-12 ME MEP-2018-46A patent/ME03011B/me unknown
- 2014-03-12 US US14/206,722 patent/US8969352B2/en active Active
- 2014-03-12 EP EP19193122.9A patent/EP3622956B9/en active Active
- 2014-03-12 EP EP17206491.7A patent/EP3363438B1/en active Active
- 2014-03-12 RS RS20180158A patent/RS56875B1/sr unknown
- 2014-03-12 JP JP2016501487A patent/JP6275815B2/ja active Active
- 2014-03-12 EA EA201591703A patent/EA029276B1/ru unknown
- 2014-03-12 JO JOP/2014/0092A patent/JOP20140092B1/ar active
- 2014-03-12 HU HUE17206491A patent/HUE047592T2/hu unknown
- 2014-03-12 CR CR20210523A patent/CR20210523A/es unknown
- 2014-03-12 HU HUE19193122A patent/HUE063608T2/hu unknown
- 2014-03-12 DK DK14717576.4T patent/DK2970314T3/en active
- 2014-03-12 PT PT147175764T patent/PT2970314T/pt unknown
- 2014-03-12 CN CN201480027437.2A patent/CN105308048B/zh active Active
- 2014-03-12 AU AU2014248680A patent/AU2014248680B2/en active Active
- 2014-03-12 EP EP23176328.5A patent/EP4272824A3/en not_active Withdrawn
- 2014-03-12 HR HRP20230633TT patent/HRP20230633T1/hr unknown
- 2014-03-12 DK DK17206491T patent/DK3363438T3/da active
- 2014-03-12 RS RS20230703A patent/RS64551B9/sr unknown
- 2014-03-12 HR HRP20180303TT patent/HRP20180303T1/hr unknown
- 2014-03-12 MX MX2018015165A patent/MX368466B/es unknown
- 2014-03-13 UY UY0001035409A patent/UY35409A/es not_active Application Discontinuation
- 2014-03-13 AR ARP140100967A patent/AR095423A1/es active IP Right Grant
- 2014-11-19 NO NO14808529A patent/NO3107630T3/no unknown
-
2015
- 2015-01-26 US US14/605,387 patent/US9447117B2/en active Active
- 2015-08-10 IL IL240466A patent/IL240466B/en active IP Right Grant
- 2015-08-24 CR CR20150433A patent/CR20150433A/es unknown
- 2015-09-02 PH PH12015501929A patent/PH12015501929A1/en unknown
- 2015-09-10 NI NI201500130A patent/NI201500130A/es unknown
- 2015-09-11 CL CL2015002609A patent/CL2015002609A1/es unknown
- 2015-10-12 ZA ZA2015/07562A patent/ZA201507562B/en unknown
-
2016
- 2016-08-26 US US15/248,945 patent/US9845333B2/en active Active
-
2017
- 2017-04-04 US US15/478,888 patent/US10183953B2/en active Active
-
2018
- 2018-03-09 CY CY20181100284T patent/CY1120024T1/el unknown
- 2018-07-03 AU AU2018204835A patent/AU2018204835B2/en active Active
-
2019
- 2019-02-03 IL IL264606A patent/IL264606A/en unknown
- 2019-11-08 HR HRP20192032TT patent/HRP20192032T1/hr unknown
- 2019-12-02 CY CY20191101261T patent/CY1122392T1/el unknown
-
2023
- 2023-07-25 CY CY20231100361T patent/CY1126106T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL264606A (en) | 2- Converted azabicycles and their use as orexin receptor modulators | |
| IL240929B (en) | 7- Converted azabicycles and their use as orexin receptor modulators | |
| IL245733A0 (en) | aplnr modulators and their uses | |
| IL240166A0 (en) | spiro-lactam modulators of the NMDA receptor and their uses | |
| IL240164A0 (en) | spiro-lactam modulators of the NMDA receptor and their uses | |
| IL240163A0 (en) | spiro-lactam modulators of the NMDA receptor and their uses | |
| IL240162B (en) | spiro-lactam modulators of the NMDA receptor and their uses | |
| IL240165A0 (en) | spiro-lactam modulators of the NMDA receptor and their uses | |
| ZA201800827B (en) | Substituted 4-azaindoles and their use as glun2b receptor modulators | |
| GB201305277D0 (en) | Novel combination and use | |
| ZA201405392B (en) | Substituted phenylimidazopyrazoles and use thereof | |
| GB201307989D0 (en) | Novel combinations and use | |
| GB201315713D0 (en) | Train set | |
| EP3013851A4 (en) | MODULATORS OF BRADYKININ RECEPTORS AND THEIR USE |